Compare Ross Stores, Inc. (ROST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Viatris Inc — how do they compare? Ross Stores, Inc. trades at $223.1 (market cap $71.94B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Ross Stores, Inc. is far larger — about 3.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Viatris Inc for 57 Days on average.
| ROST | VTRS | |
|---|---|---|
Market Cap | $71.94B | $20.03B |
Volume | 2,002,519 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $18.27 |
52-Week Low | $147.71 | $9.74 |
Typical Hold Time | 48 Days | 57 Days |
Enterprise Value | $72.39B | $32.15B |
Dividend Yield | 0.79% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.53, up 0.59% with strong fundamental performance including three consecutive earnings beats and robust profitability metrics. The stock shows bearish technical signals despite positive analyst sentiment, with 64% buy ratings and a $274.14 consensus price target representing 22% upside potential. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents compelling investment potential with strong earnings momentum and expanding profit margins, though technical weakness and competitive pressures warrant caution. The company's value-focused strategy and operational discipline support continued growth, while elevated valuation multiples and market volatility pose near-term risks for shareholders.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
